Some very good information in there that points out that with...

Some very good information in there that points out that with all of these drugs, there will be a lot of patients that won't have good resilts from one option but are then encouraged by the experts to try another because often another option will be found that does work. That's great for Spontan because it means there are and always will be more people that are looking for something new.
They also pointed out that for some patients, oral tablets can work in as little as 15 minutes but for those same patients, Spontan works in just 5 minutes and there are other cases in which the oral tablets can take half an hour or more to work but Spontan only takes 5-10minutes for those patients too.
Melissa did say that they have had very good results with Spontan and it sounds like they are quite happy to recommend it to a wide range of patients. I got the impression that it would be her first choice for a majority even if not suitable for ever patient.
Listening to this podcast it was interesting to hear how many patients have limited success with tablets and even injectibles but then have good results using Spontan as a "top up", as well as the advantages of using Spontan as a first choice for the majority of patients because of its quicker onset, less side effects and even the convenience of being able to carry it around in your pocket and not needing a glass of water to take with a pill - eg if in a car etc.
The fact that so many patients have limited success with other options and are recommended to try alternatives like Spontan, makes me rethink how much narket share Spontan can achieve. I was previously looking at 1-2% and using 3-5% as a possible upside case but I now think 10-15% is sounding quite realistic within just a few years of full market entry following regulatory approval. I think these pre-approval prescriptions in Australia and the US early next year will be great for increasing awareness and that should lead to a much quicker ramp up in sales post regulatory approval.